Aim We investigated whether P144, a synthetic peptide from transforming growth factor-b 1 (TGF-b 1 ) type III receptor betaglycan, exhibits cardiac antifibrotic properties.
Introduction
An interstitial and perivascular accumulation of fibrillar collagen, namely collagen type I, has been demonstrated in the myocardium of animals and humans with arterial hypertension and left ventricular hypertrophy (LVH). 1 Transforming growth factor-b 1 (TGF-b 1 ) is a cytokine that induces an increase in collagen type I synthesis in rat cardiac fibroblasts in culture, 2, 3 and appears to play a pivotal role in promoting myocardial fibrosis in vivo. In fact, overexpression of TGF-b 1 in transgenic mice results in myocardial fibrosis. 4 In contrast, age-associated myocardial fibrosis is diminished in heterozygous TGF-b 1 -deficient mice. 5 An association of TGF-b 1 overexpression with fibrosis has been reported in the myocardium of spontaneously hypertensive rats (SHR) with LVH. 6, 7 In addition, an association has been reported between an excess of circulating TGF-b 1 and serum markers of enhanced collagen type I synthesis in hypertensive patients with LVH. 8, 9 It has been reported previously that the peptide P144, encompassing amino acids 730-743 from the membraneproximal ligand-binding domain of TGF-b 1 type III receptor, also called betaglycan, is able to interfere with TGF-b 1 binding to its cellular receptors and block the biological activity of this cytokine. 10, 11 Furthermore, systemic administration of P144 showed potent antifibrotic activity in the cirrhotic liver of rats receiving CCl 4 , 11 and the skin of bleomycin-treated C3H mice with scleroderma lesions. 12 Whether P144 also possesses cardiac antifibrotic activity in arterial hypertension remains unknown. Thus, we have tested the effects of chronic intraperitoneal administration of the peptide on a number of parameters assessing TGF-b 1 -dependent signalling activity and collagen type I synthesis, cross-linking and deposition in SHR with LVH. In addition, the effects of P144 on TGF-b 1 stimulated cultured rat cardiac fibroblasts have been also examined.
Methods

In vivo study
Animals
The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No 85-23, revised 1996), 13 and was approved by the Ethical Committee for Animal Experimentation of the University of Navarra. Rats were provided by Harlan UK Limited (Bicester, UK). Ten-week-old male Wistar-Kyoto rats (WKY) (n ¼ 10, vehicle-treated WKY or V-WKY), and 10-week-old male SHR (n ¼ 10, vehicle-treated SHR or V-SHR) received vehicle (saline solution) intraperitoneally for 12 weeks and then were killed at the age of 22 weeks. In addition, 10-week-old SHR (n ¼ 10, P144-treated SHR or P144-SHR) were treated with intraperitoneal P144 for 12 weeks and then killed. The peptide was dissolved in saline solution, and the concentration was adjusted for the body weight to obtain an average daily dose of 1 mg/kg body weight per day. This dose was selected because it has been demonstrated previously in rodents that P144 exhibits hepatic and cutaneous antifibrotic activity at doses above 0.5 mg/kg body weight per day. 11, 12 All rats were housed in individual cages with free access to standard rat chow and tap water in a quiet room with constant temperature (20-228C) and humidity (50-60%). Before they were killed by decapitation, the rats were weighed and anaesthetized with Ketamine 75 mg/kg (Imalgene 1000, Merial) and Xylazine 5 mg/kg (Rompun, Bayer). One group of untreated WKY (n ¼ 10) and one group of untreated SHR (n ¼ 10) were sacrificed at 10 weeks of age to determine the baseline values of the different parameters tested.
Measurement of blood pressure
Systolic blood pressure (SBP) and diastolic BP (DBP) were measured in all rats every 2 weeks by the standard tail-cuff method using an LE 5007 Pressure Computer (Letica Scientific Instruments, Barcelona, Spain). 14 
Preparation of tissue samples
After sacrifice, the heart was removed intact and weighed in each rat. The cardiac index (CI) was calculated by dividing the heart weight by the body weight in each animal. The left ventricle (LV) was then dissected and cut perpendicular to the apex-to-base axis into three pieces. Two of these pieces were frozen for mRNA and protein analysis, and the remaining piece was used for histomorphological and colourimetric studies.
Real-time RT-PCR
The mRNA was isolated from total RNA with the Oligotex mRNA kit (Qiagen, Hilden, Germany). To determine mRNA levels of procollagen type I a 1 chain (procollagen a 1 (I)), and of lysyl oxidase (LOX), which is the enzyme responsible of collagen cross-linking, 15 reverse transcription-polymerase chain reaction (RT-PCR) was performed as recently described. 16 For visualization of betaglycan mRNA, the amplification was followed by electrophoresis. The following specific TaqMan MGB fluorescent probes for rat were used (Applied Biosystems, Foster City, CA, USA): Procollagen a 1 (I) (Rn 01463848), LOX (Rn 00566984), betaglycan (Rn 1531150), and 18S ribosomal RNA (4333760F) as endogenous control. Data were normalized to 18S ribosomal RNA expression and expressed as relative (in arbitrary units).
Western blot
For protein extraction, frozen tissues were solubilized in Urea-Thiourea buffer. To analyze the expression of the nonglycosilated (38 kDa) and glycosilated (42 kDa) isoforms of connective tissue growth factor (CTGF), the phosphorylated form of Smad 2 (P-Smad2), collagen type I, and LOX, these proteins were separated by electrophoresis. Specific rabbit polyclonal antibody against Smad-2 (Chemicon, Temecula, CA, USA) was incubated at a dilution of 1:500, overnight at 48C. Specific antibodies against CTGF (Affinity Bioreagents, Golden, CO, USA) and collagen type I (Biogenesis, Kingston, NH, USA) were incubated at a dilution of 1:1000, overnight at 48C. Specific rabbit polyclonal antibody against LOX zymogen and active form (Abcam, Cambridge, UK) was incubated at a dilution of 1:100, overnight at 48C. Bands were detected by incubation with peroxidase-conjugated anti-rabbit (Amersham Biosciences, Little Chalfont, UK). Protein expression was visualized with the ECL-Plus chemiluminiscence system (Amersham Biosciences) and autoradiograms were analyzed using an automatic densitometer (Quantity One, Bio-Rad, Hercules, CA, USA). The blots were reprobed with a monoclonal b-actin antibody (Sigma, Saint Louis, MO, USA) as a control for loading. Data are expressed as relative to b-actin expression (in arbitrary units).
Histomorphological analysis
Histological evaluation was performed without knowledge of which animal the tissue section had been obtained. Myocardial samples were immediately fixed in 4% buffered formalin, embedded in paraffin, and serially sectioned in 4 mm thick sections. Sections were stained with collagen-specific picrosirius red (Sirius red F3BA in aqueous picric acid) according to Dolber and Spach. 17 The fraction of myocardial tissue occupied by collagen fibers or collagen volume fraction (CVF) was determined as a percentage by quantitative morphometry with an automated image analysis system (AnalySYS, Soft Imaging System GmbH, Hammer, Germany). Sections were analyzed under an automatized microscope (Â20), and all the fields covering myocardial tissue section were digitized. Stained collagen areas (dark) were segmented by interactive gray-level thresholding of shading-corrected images, and then the subendocardial regions were interactively discarded. The abnormal accumulation of fibrous tissue or CVF was calculated as the sum of all connective tissue areas divided by the sum of all connective tissue and muscle areas in all the fields analyzed in each section. As previously described, 18 two patterns of collagen deposition were defined: interstitial (surrounding groups of cardiomyocytes), and perivascular (around intramyocardial vessels).
Colourimetric assays
To evaluate the degree of cross-linking of collagen molecules to form collagen fibers, the amounts of cross-linked (insoluble) and non-cross-linked (soluble) collagen were determined using two colourimetric assays: Fast Green-Sirius Red to obtain total collagen 19 and Sircol-based assay to obtain soluble collagen. 20 The degree of cross-linking was calculated as the ratio between the insoluble and the soluble forms of collagen.
Determination of anti-P144 antibodies
Anti-P144 antibodies were titrated in serum samples from P144-SHR by enzyme-linked immunosorbent assay as previously described. 21 Serum titers of antibodies were expressed as the serum dilution that corresponds with three times the optical density obtained with the negative control serum.
In vitro study 2.2.1 Cell cultures and preparation of samples
Rat-2 cell line of cardiac fibroblasts were purchased from American Type Culture Collection (ATCC) and maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (FBS, Invitrogen), Penicilin-Streptomycin solution (Invitrogen), and Fungizone (Invitrogen). Rat-2 cells were seeded at a density of 5.25 Â 10 5 cells in tissue culture flask T-75 (Nunc, Roskilde, Denmark) and allowed to adhere overnight. Cells were then incubated in reduced-serum medium (1% FBS) for 24 h prior to TGF-b 1 stimulation. Four groups of fibroblasts were used: (i) cells incubated in reduced serum media, (ii) cells incubated in reduced serum media containing TGF-b 1 , (iii) cells incubated in reduced serum media containing P144, and (iv) cells incubated in reduced serum media containing TGF-b 1 and P144, for 18 h prior to harvesting. In a first group of experiments, concentration-response curves for the response of fibroblasts to 1 to 0.00005 ng/mL of TGF-b 1 were performed in order to determine the concentration able to induce the submaximal expression of procollagen a 1 (I) mRNA, 0.01 ng/mL of TGF-b 1 . In a second group of experiments, the fibroblasts were incubated for 18 h with different concentrations of P144 to determine the concentration able to block the effect of 0.01 ng/mL of TGF-b 1 on procollagen a 1 (I) mRNA, 200 mg/mL of P144. After treatment, cells were trypsinized and pelleted. Cell pellets were washed in phosphate-buffered solution (Invitrogen) and centrifuged at 1100 g for 5 min at 48C and then used for total RNA isolation and protein extraction. This experiment was repeated seven times.
Real-time RT-PCR
The extraction of mRNA for determination of procollagen a 1 (I) and 18S ribosomal RNA was performed as described earlier.
Western blot
The extraction and the analysis of P-Smad2 and the 38 and 42 kDa isoforms of CTGF were performed in cell lysates as described earlier.
Statistical analysis
Results are given as mean + SEM computed from the average measurements obtained from each group of cells and rats. To analyze the differences between the two groups of untreated 10-week-old rats an unpaired Student's t-test was performed once normality had been proven (Shapiro-Wilks test); otherwise, a nonparametric test (Wilcoxon) was used to check differences between the two groups. To analyze the differences among the three groups of 22-week-old rats and the four groups of cells, a one-way ANOVA followed by a Scheffe's test was performed once normality had been proven (Shapiro-Wilks test); otherwise, a non-parametric test (Kruskall-Wallis) followed by a Mann-Whitney U-test (adjusting the a-level by Bonferroni inequality) was used to check differences between two groups. The relation between variables was tested calculating Pearson correlation coefficient and, when applicable, Spearman correlation coefficient. Multivariable linear regression models were used to assess the independent relationship between the variables of interest (P-Smad2 and CTGF isoforms) and parameters of myocardial fibrosis (CVF, collagen type I, and collagen cross-linking) after adjustment for SBP and DBP, previously found to be associated with fibrosis in univariable regression models.
Results
In vivo findings
3.1.1 Findings in untreated 10-week old rats At 10 weeks of age, SHR exhibited higher (P , 0.01) values of SBP, DBP, and CI than WKY rats ( Table 1) . No differences between the two groups of rats were found in parameters assessing the synthesis (i.e. expression of procollagen type I mRNA and collagen type I) and deposition (CVF) of collagen ( Table 1) . Whereas a tendency to increased collagen crosslinking was observed in SHR compared with WKY, a higher (P , 0.05) expression of active LOX was seen in the myocardium of SHR than in WKY ( Table 1) . No differences were found in the expression of LOX mRNA and LOX zymogen between the two groups of rats. In addition, the values of parameters assessing TGF-b 1 -dependent signalling pathway (i.e. expression of P-Smad2 and CTGF isoforms) were similar in the two groups of rats (Table 1) . Thus, at the beginning of the experiment the hypertensive rats presented with LVH but not with myocardial fibrosis or data suggesting enhanced myocardial TGF-b 1 activity.
To detect the presence of betaglycan in the rat heart, RT-PCR followed by electrophoresis separation was performed. The presence of betaglycan mRNA was identified in the myocardium from all WKY and SHR animals (data not shown). No differences in betaglycan expression were observed between WKY (11.67 + 0.86 arbitrary units) and SHR (13.04 + 1.35 arbitrary units).
Safety of P144
Antibody titers against P144 were measured in blood in all SHR treated with P144 at the end of the treatment period. Only two rats exhibited marginal titers (,1/50), suggesting that this peptide is a weak immunogen in this rat strain.
All P144-treated SHR survided until the end of the treatment period. No significant differences in the body weight of P144-treated SHR compared with vehicle-treated SHR were observed (data not shown). Preliminary toxicological examination of several organs (liver, lung, kidney, spleen, intestine, tongue, and testes) from P144-treated SHR revealed no macroscopic signs of toxicity.
Effects of P144 on BP and LVH
Compared with V-WKY the values of SBP and DBP remained elevated in V-SHR throughout the experimental 12-week period. BP values were lower (P , 0.01) in P144-SHR than in V-SHR just during the last 2 weeks of treatment (Figure 1) . However, at 22 weeks of age, BP was still higher (P , 0.01) in P144-SHR than in V-WKY ( Table 2) . The CI was similar in P144-SHR than in V-SHR ( Table 2) . Thus, P144-SHR exhibited higher (P , 0.05) CI than V-WKY ( Table 2) .
Effects of P144 on TGF-b 1 -dependent signalling activity
The myocardial expression of P-Smad2 was higher (P , 0.01) in V-SHR than in V-WKY (Figure 2) . The administration of P144 reduced (P , 0.05) the expression of P-Smad2 in P144-SHR compared with V-SHR (Figure 2) . The expression of this molecule was similar in P144-SHR than in V-WKY (Figure 2) .
Whereas the myocardial expression of 42 kDa CTGF was higher (P , 0.01) in V-SHR than in V-WKY, the expression of 38 kDa CTGF was similar in the two groups of rats ( Figure 3) . The administration of P144 was accompanied by decreased (P , 0.01) expression of the two CTGF isoforms in P144-SHR compared with V-SHR (Figure 3) . No significant differences in CTGF expression were observed between P144-SHR and V-WKY (Figure 3) .
Effects of P144 on collagen type I synthesis
As shown in Table 2 , V-SHR showed higher (P , 0.05) expression of both procollagen a 1 (I) mRNA and collagen type I protein than V-WKY and P144-SHR. No significant differences in these two parameters were found between V-WKY and P144-SHR.
Effects of P144 on myocardial fibrosis
The degree of collagen cross-linking, as assessed by the ratio of insoluble to soluble collagen, was higher (P , 0.01) in V-SHR than in V-WKY ( Table 2) . P144 administration decreased (P , 0.05) collagen cross-linking in P144-SHR compared with V-SHR ( Table 2) . No differences in this parameter were observed in P144-SHR compared with V-WKY.
LOX expression was higher, both at the mRNA and protein levels, in V-SHR than in V-WKY ( Table 2) . P144-SHR exhibited decreased levels of LOX mRNA and protein compared with V-SHR ( Table 2) . Whereas the expression of LOX mRNA and LOX zymogen were normalized in P144-SHR, the expression of active LOX remained abnormally high in these rats ( Table 2) .
CVF was increased (P , 0.01) in V-SHR compared with V-WKY ( Table 2) . After P144 administration CVF was reduced (P , 0.05) in P144-SHR compared with V-SHR ( Table 2) . No differences were found in this parameter between P144-SHR and V-WKY ( Table 2 ). Figure 4 shows representative pictures of collagen deposition in the myocardium of one animal from each group of rats. Whereas picrosirius red stained very slightly the interstitium and the region around the intramyocardial vessels in one V-WKY (upper panels), large positively stained bands and strands were observed across the interstitium and around the vessels, respectively, in one V-SHR (middle panels). The interstitium and the perivascular region were slightly stained in one P144-SHR (lower panels). 
Analysis of associations
As shown in Thus, we evaluated the expression of P-Smad2 and the two isoforms of CTGF. As shown in Table 4 and Figure 5 , the expression of P-Smad2 was stimulated (P , 0.01) in fibroblasts incubated with TGF-b 1 compared with control cells. The expression of P-Smad2 was reduced (P , 0.01) to control levels in fibroblasts incubated with TGF-b 1 and P144 ( Table 4 and Figure 5 ). The expression of 38 and 42 kDa isoforms of CTGF was stimulated (P , 0.01) in fibroblasts incubated with TGF-b 1 compared with control cells (Table 4 and Figure 5 ). A reduced (P , 0.01) expression of both isoforms to control levels was found in cells incubated with TGF-b 1 and P144 ( Table 4 and Figure 5 ). TGF-b 1 also stimulated (P , 0.01) procollagen a1 (I) mRNA expression in fibroblasts ( Figure 6 ). The expression of procollagen a1 (I) mRNA in cells incubated with TGF-b 1 and P144 decreased (P , 0.01) to values measured in control cells ( Figure 6 ).
No differences in all these parameters were observed between fibroblasts incubated with P144 and control fibroblasts ( Table 4 , Figures 5 and 6 ). 
Discussion
The main findings of this study are as follows: (i) chronic administration of P144 is associated with decreased TGF-b 1 -dependent signalling activity and reduced collagen type I synthesis and cross-linking in the myocardium of SHR; (ii) myocardial fibrosis is prevented in SHR chronically treated with P144; and (iii) P144 is able to block TGF-b 1 -dependent signalling activity, as well as collagen type I synthesis in cultured rat cardiac fibroblasts.
Increased cardiac collagen type I synthesis and deposition have been described in the hypertrophied LV of adult 22 and aged SHR. 23 The available data suggest that fibrosis in this model is not simply due to mechanical overload imposed on the LV wall by systemic hypertension, but can be also the result of the enhanced local activity of profibrotic factors such as TGF-b 1 .
6,7 Our data add strong support to this notion. In fact, whereas collagen type I synthesis, crosslinking, deposition, and TGF-b 1 -dependent signalling activity were normal in young rats with increased BP and LVH (10-week-old SHR), an association was found between excessive collagen type I synthesis and cross-linking, and deposition and enhanced TGF-b 1 -dependent signalling activity in adult rats with increased BP (22-week-old SHR). Thus, the SHR model is adequate to explore the ability of measures aimed to prevent myocardial fibrosis that develops with the chronic exposure to both hypertension and nonhaemodynamic factors. TGF-b 1 type III receptor or betaglycan is the most abundant TGF-b 1 binding protein at the cell surface. 24 Betaglycan potentiates TGF-b 1 binding to the signalling type I and II receptors and, therefore, may be involved in ligand presentation. 25 Betaglycan overexpression has been found to be associated with stimulated procollagen a 1 (I) mRNA synthesis in human fibroblasts. 26 The presence of betaglycan has been reported previously in the embryonic 27 and fetal 28 rat heart, and available data suggest that it acts to regulate the contribution of TGF-b 1 to cardiac development. 29 Data here presented show for the first time that this receptor is also expressed in the developed rat heart, suggesting that it regulates TGF-b 1 -mediated cardiac actions in the post-natal life.
P144 was derived in our laboratory from the sequence of the extracellular region of betaglycan and it was predicted as a potential binder to TGF-b 1 by a computer program. 13 It has been reported previously that P144 blocks the binding of TGF-b 1 to its type I and II receptors, counteracts the antiproliferative effects of TGF-b 1 on MV1Lu cells, and inhibits TGF-b 1 -induced activation of procollagen a 2 (I) gene expression in a fibroblast cell line. 13 Findings from the current study expand these data by showing that P144 blocks the ability of TGF-b 1 to stimulate P-Smad2 and CTGF isoforms in rat cardiac fibroblasts. In addition, we also show that P144 decreases procollagen a1 (I) mRNA expression and collagen type I synthesis in these cells. It thus is tempting to speculate that P144 blocks TGF-b 1 -dependent signalling pathway and transcriptional activity in cardiac fibroblasts.
Myocardial fibrosis has been proposed as a major determinant of altered LV function leading to chronic heart failure in patients with cardiac diseases. 30 In this context, a number of strategies have been investigated to prevent fibrosis in hypertensive heart disease. 31 Most of this research has Figure 4 Myocardial tissue from one vehicle-treated normotensive WistarKyoto rat (V-WKY) (upper panels), one vehicle-treated spontaneously hypertensive rat (V-SHR) (medium panels), and one P144-treated SHR (P144-SHR) (lower panels). Sections were stained with picrosirius red and collagen fibers were identified in red. Collagen tissue was seen as bands surrounding groups of cardiomyocytes (interstitial collagen, left panels) and as strands localized around intramyocardial vessels (perivascular collagen, right panels). Magnification Â20. focused on the antifibrotic effectiveness of drugs interfering with the axis angiotensin II-aldosterone-TGF-b 1 . In the current study, we demonstrate that SHR treated with P144 do not develop myocardial fibrosis as they do SHR treated with vehicle. On the other hand, we found that chronic administration of P144 to SHR is associated with reduced TGF-b 1 -dependent signalling activity and decreased synthesis and cross-linking of collagen type I in the myocardium of these rats. In addition, the expression of the LOX enzyme, responsible of collagen cross-linking, was also reduced by treatment with P144 in SHR. Collectively, these data suggest that the cardiac antifibrotic effect of P144 in SHR can be due to its ability to both reduce the synthesis of collagen type I and diminish LOX-mediated collagen crosslinking which, in turn, may be related with the inhibition of TGF-b 1 activity in cardiac fibroblasts and other cardiac cells.
Some limitations of the current study must be recognized. At the time of sacrifice, the values of BP were lower in P144-SHR than in V-SHR. However, several arguments suggest that this effect can be negligible in terms of its impact on myocardial fibrosis. First, as shown in Figure 1 , the decrease in BP in P144-SHR compared with vehicle treated-SHR did not reach statistical significance until 2 weeks before the animals were sacrificed for assessment of cardiac parameters. Second, the values of BP measured during the last weeks of treatment in P144-SHR were well above the values measured during the same time in V-WKY rats, thus SHR treated with P144 remained hypertensive during all the experimental period. Third, we found that P144-SHR exhibited no changes in CI compared with V-SHR, and previous studies performed in SHR revealed that LVH is a sensitive marker of the true haemodynamic impact on the heart of high BP levels. 32 Fourth, as shown by Shi et al., 33 normalization of BP by chronic administration of hydralazine did not prevent myocardial fibrosis in adult SHR. Finally, we demonstrate that P144 prevents the signalling and pro-fibrotic activity of TGF-b 1 in cultured rat cardiac fibroblasts, thus supporting a role for a direct myocardial antifibrotic effect of the peptide. Anyway, it is not surprising that systemic TGF-b 1 receptor blockade is accompanied by the decrease in BP, since this cytokine may act bifunctionally to elevate BP, first by altering levels of vasoactive mediators (e.g. endothelin-1) and, second, by changing vessel wall architecture to increase peripheral resistance. 34 Another limitation of this study is that although TGF-b 1 has been shown to activate other mediators such MAPK cascades (ERK, JNK, p38, PI3K), PP2A phosphatases, and Rho family members, 35 these pathways were not tested in this study. Unlike the Smad pathway, however, these alternative pathways are activated by the cytokine in a context-and cell-type specific manner, and their biochemical links to the activated receptors are largely unknown. We therefore consider that Smads are the most specific substrates for the TGF-b 1 receptor kinases. This is particularly relevant for the heart, since it has been shown that the myocardial fibrotic effects of TGF-b 1 are primarily mediated through Smad2 phosphorylation. 36 Finally, we have not assessed the enzymatic systems involved in collagen degradation. The fibrogenic potential of TGF-b 1 is not just due to its ability to stimulate collagen synthesis, but also to inhibit collagen degradation through inhibition of matrix metalloproteinases (MMPs) and stimulation of tissue inhibitors of MMPs. 37, 38 Thus, further studies are required to investigate whether P144 also modifies the ability of TGF-b 1 to alter LOX activity and the balance between MMPs and their inhibitors in the rat myocardium.
In conclusion, our findings support a critical role for TGF-b 1 in the development of myocardial fibrosis in adult SHR. Whereas the available anti-TGF-b 1 measures aimed to prevent cardiac fibrosis associated with arterial hypertension have failed due to their potential adverse consequences, including toxicity and immunological alterations, 39 data here reported show that in the SHR model P144 is a safe and effective cardiac antifibrotic compound. Therefore, we suggest that betaglycan-derived peptides may represent a new strategy to prevent myocardial fibrosis in hypertensive heart disease.
